Previous 10 | Next 10 |
Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q3 earnings results on Thursday, October 27th, after market close. The consensus EPS Estimate is $0.62 and the consensus Revenue Estimate is $1.33B (+1.5% Y/Y). Over the last 2 years, EW has beaten EPS estima...
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022 PR Newswire IRVINE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 ...
Summary We discuss our top performance detractors and contributors for the third quarter. We present an in-depth company commentary about Alphabet. We lead off this letter with the same Ford Administration WIN graphic from our last letter and a short summary. Fed to ...
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years. Minimally invasive surgical procedures...
Summary Wedgewood Partners’ 13F portfolio value decreased from $709M to $579M this quarter. They added Pool Corp and increased PayPal Holdings and First Republic Bank while reducing Visa, Tractor Supply, Progressive Corporation, and Starbucks. Their top five positions a...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL PR Newswire BOSTON , Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomiz...
The US FDA has approved Edwards Lifesciences' ( NYSE: EW ) PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair. The system is used for patients with degenerative mitral regurgitation. It is also engineered with an intuitive cat...
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION PR Newswire IRVINE, Calif. , Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the compan...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this update in regard to the status of the proposed return of capital announced on June 19, 2024 . The Company has prepared and mailed its ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
2024-07-25 16:00:08 ET Pito Chickering from Deutsche Bank issued a price target of $85.00 for EW on 2024-07-25 13:36:00. The adjusted price target was set to $85.00. At the time of the announcement, EW was trading at $60.58. The overall price target consensus is at $109....